Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review

Introduction and Purpose: Obesity is an escalating global health challenge, affecting over 2 billion individuals worldwide, contributing to many challenges for healthcare providers such as cardiovascular disorders, cancers, and type 2 diabetes mellitus. There is a need for effective treatments targe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aleksander Jentkiewicz, Esmail Haj Obeid, Jakub Ulrych, Jan Krupa, Maciej Malinowski, Michał Krasowski, Alicja Kalinowska, Wiktoria Pietras, Adrian Kozieł, Zofia Kurek
Format:	Article
Language:	English
Published:	Kazimierz Wielki University 2025-02-01
Series:	Journal of Education, Health and Sport
Subjects:	tirzepatide semaglutide weight loss GLP-1 receptor agonists obesity treatment liraglutide
Online Access:	https://apcz.umk.pl/JEHS/article/view/57712
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Role of physical activity in GLP-1 receptor agonist therapy for obesity treatment
by: Łukasz Zdziebkowski, et al.
Published: (2025-07-01)

A comparison of Glucagon-like peptide-1 receptor agonists on weight change, side effects, and quality of life in Kuwait
by: Saleh Alali, et al.
Published: (2025-05-01)

Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on weight regain after bariatric surgery: a real-world retrospective observational study
by: Anders Boisen Jensen, et al.
Published: (2025-04-01)

Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
by: Hoffmann K, et al.
Published: (2025-08-01)

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review
by: Juliana West, et al.
Published: (2025-04-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Revisiting the role of novel weight management medications and bariatric surgery
by: LIANG Hui
Published: (2025-06-01)

The Risk of Vestibular Disorders with Semaglutide and Tirzepatide: Findings from a Large Real-World Cohort
by: Eman A. Toraih, et al.
Published: (2025-04-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Evolving Insights into Pathogenesis, Progression, and Personalized Treatment Approaches
by: Paweł Kukiełka, et al.
Published: (2025-07-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
by: Mohammad Amin Karimi, et al.
Published: (2025-05-01)

Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology
by: Е. L. Nasonov, et al.
Published: (2024-04-01)

The Impact of GLP-1 Receptor Agonists on Women's Reproductive Health: A Review
by: Marta Wolszczak, et al.
Published: (2025-06-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Impact of Fasting on Physical Activity Motivation and Weight Reduction in Patients Administered Glucagon-Like Peptide-1 Agonists: A Qualitative Study
by: Almaqhawi A, et al.
Published: (2025-01-01)

Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis
by: Samuel N. Goldman, BS, et al.
Published: (2025-06-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Patient-reported outcomes of glucagon-like peptide-1 agonists on hidradenitis suppurativa severity
by: Radhika Gupta, BA, et al.
Published: (2025-08-01)

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado
by: Michael J. DiStefano, et al.
Published: (2025-12-01)

Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01)

Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide
by: Zsombor I. Hegedűs, et al.
Published: (2025-06-01)

Rhabdomyolysis associated with the use of tirzepatide
by: Kunal Sonavane, et al.
Published: (2025-04-01)

Randomised trial comparing weight loss through lifestyle and GLP-1 receptor agonist therapy in people with MASLD
by: Ahmad Moolla, et al.
Published: (2025-05-01)

Tirzepatide - role in obesity, health and physical wellness. Information overview
by: Anna Hanslik, et al.
Published: (2025-02-01)

Glucagon-like peptide 1 receptor agonists: A new approach to type 2 diabetes management
by: Lynn Lambert
Published: (2013-12-01)

Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide
by: Noha Hafeez, et al.
Published: (2024-12-01)

Case Report: Rhabdomyolysis following initiation of tirzepatide
by: Jonas Michael Bodanowitz, et al.
Published: (2025-08-01)

Novel findings regarding treatment obesity and weight-related comorbidities – the systemic literature review
by: Karina Urbańska, et al.
Published: (2025-01-01)

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta‐Analysis of Direct Comparative Studies
by: Jimmy Wen, et al.
Published: (2025-05-01)

The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists in Polycystic Ovary Syndrome: A Narrative Review
by: Kamil Turlej, et al.
Published: (2025-07-01)

The effect of beinaglutide as an glucagon-like peptide-1 receptor agonists on cardiometabolic factors: a systematic review and meta-analysis
by: Yan Xu, et al.
Published: (2025-04-01)

Multiomics insight into the role of glucagon‐like peptide‐1 receptor agonists in heart failure
by: Yuhang Tao, et al.
Published: (2025-08-01)

Glucagon-Like Peptide-1 Receptor Agonists in Obesity Management: Mechanisms, Efficacy, and Safety
by: Michał Stasiak, et al.
Published: (2025-06-01)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

A narrative review of glucagon-like peptide-1 receptor agonists prior to deep sedation or general anesthesia
by: Luigi Vetrugno, et al.
Published: (2025-03-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
by: Mohammed Sallam, et al.
Published: (2025-04-01)

The Efficacy and Safety of Tirzepatide in Patients with Diabetes and/or Obesity: Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Ligang Liu, et al.
Published: (2025-04-01)